scholarly journals Genetic variants in the vitamin D pathway genesVDBP andRXRAmodulate cutaneous melanoma disease-specific survival

2016 ◽  
Vol 29 (2) ◽  
pp. 176-185 ◽  
Author(s):  
Jieyun Yin ◽  
Hongliang Liu ◽  
Xiaohua Yi ◽  
Wenting Wu ◽  
Christopher I. Amos ◽  
...  
Keyword(s):  
Vitamin D ◽  
Cutaneous Melanoma ◽  
Genetic Variants ◽  
Disease Specific Survival ◽  
Disease Specific

scholarly journals Genetic Variants of the Vitamin D Receptor Gene Alter Risk of Cutaneous Melanoma

2007 ◽  
Vol 127 (2) ◽  
pp. 276-280 ◽  
Author(s):  
Chunying Li ◽  
Zhensheng Liu ◽  
Zhengdong Zhang ◽  
Sara S. Strom ◽  
Jeffrey E. Gershenwald ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D Receptor ◽  
Cutaneous Melanoma ◽  
Genetic Variants ◽  
Receptor Gene ◽  
Vitamin D Receptor Gene

scholarly journals Genetic variants in the PIWI-piRNA pathway geneDCP1Apredict melanoma disease-specific survival

2016 ◽  
Vol 139 (12) ◽  
pp. 2730-2737 ◽  
Author(s):  
Weikang Zhang ◽  
Hongliang Liu ◽  
Jieyun Yin ◽  
Wenting Wu ◽  
Dakai Zhu ◽  
...  
Keyword(s):  
Genetic Variants ◽  
Disease Specific Survival ◽  
Pirna Pathway ◽  
Disease Specific

CCR5 gene polymorphism in patients with cutaneous melanoma: Impact on survival following immunotherapy

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 21071-21071
Author(s):  
J. C. Becker ◽  
S. Ugurel ◽  
M. Zapatka ◽  
H. L. Kaufmann ◽  
D. Schrama
Keyword(s):  
Immune Responses ◽  
Cutaneous Melanoma ◽  
Stage Iv ◽  
Receptor Protein ◽  
Strong Impact ◽  
Disease Specific Survival ◽  
Ccr5 Gene ◽  
Therapeutic Modalities ◽  
Melanoma Patients ◽  
Disease Specific

21071 Background: Chemokines are supposed to influence both tumor progression and anti-tumoral immune responses. In this regard, a 32-bp-deletion polymorphism in the chemokine receptor 5 gene (CCR5Δ32) resulting in a non-functional receptor protein allows to study the potential impact of the CCR5 system on the clinical course and treatment outcome of malignant diseases. Methods: CCR5 genotyping was performed by PCR on DNA extracted from serum samples of 782 cutaneous melanoma patients with known disease history and long-term clinical follow-up. Genotypes were correlated with patient survival in consideration of different therapeutic modalities. Results: Out of 782 patients, 90 (11.5%) were heterozygous and 12 (1.5%) were homozygous for CCR5Δ32. Disease-specific survival starting from primary diagnosis was not influenced by CCR5 status. Equally, no impact of the CCR5 status could be detected on treatment outcomes of stage III patients. In 139 stage IV patients treated with immunotherapeutics, however, CCR5Δ32 was associated with a diminished survival compared to patients not carrying the Δ32 allele (p=0.029). Multivariate analysis revealed the CCR5 genotype as an independent factor impacting disease-specific survival in this patient group (p=0.0084), followed by gender (p=0.017), and type of primary (p=0.029). Vice versa, stage IV patients without immunotherapy revealed a trend towards a favorable survival when harboring CCR5?32 (p=0.12). Conclusions: The disadvantage of CCR5Δ32-bearing stage IV melanoma patients with respect to outcome of immunotherapy indicates a strong impact of the CCR5 mediator system on anti-tumoral immune responses, and should be taken into account when choosing therapeutic modalities for these patients. No significant financial relationships to disclose.

Multi-Institutional Melanoma Lymphatic Mapping Experience: The Prognostic Value of Sentinel Lymph Node Status in 612 Stage I or II Melanoma Patients

1999 ◽  
Vol 17 (3) ◽  
pp. 976-976 ◽  
Author(s):  
Jeffrey E. Gershenwald ◽  
William Thompson ◽  
Paul F. Mansfield ◽  
Jeffrey E. Lee ◽  
Maria I. Colome ◽  
...  
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Prognostic Factor ◽  
Cutaneous Melanoma ◽  
Lymphatic Mapping ◽  
Tumor Thickness ◽  
Disease Specific Survival ◽  
Melanoma Patients ◽  
Disease Free ◽  
Disease Specific

PURPOSE: To compare the effect of pathologic sentinel lymph node (SLN) status with that of other known prognostic factors on recurrence and survival in patients with stage I or II cutaneous melanoma. PATIENTS AND METHODS: We reviewed the records of 612 patients with primary cutaneous melanoma who underwent lymphatic mapping and SLN biopsy between January 1991 and May 1995 to determine the effects of tumor thickness, ulceration, Clark level, location, sex, and SLN pathologic status on disease-free and disease-specific survival. RESULTS: In the 580 patients in whom lymphatic mapping and SLN biopsy were successful, the SLN was positive by conventional histology in 85 patients (15%) but negative in 495 patients (85%). SLN status was the most significant prognostic factor with respect to disease-free and disease-specific survival by univariate and multiple covariate analyses. Although tumor thickness and ulceration influenced survival in SLN-negative patients, they provided no additional prognostic information in SLN-positive patients. CONCLUSION: Lymphatic mapping and SLN biopsy is highly accurate in staging nodal basins at risk for regional metastases in primary melanoma patients and identifies those who may benefit from earlier lymphadenectomy. Furthermore, pathologic status of the SLN in these patients with clinically negative nodes is the most important prognostic factor for recurrence. The information from SLN biopsy is particularly helpful in establishing stratification criteria for future adjuvant trials.

Increased size of sentinel lymph node is associated with disease-specific survival for cutaneous melanoma

2015 ◽  
Vol 221 (4) ◽  
pp. e130
Author(s):  
Brandon Chapman ◽  
Alessandro Paniccia ◽  
Justin Merkow ◽  
Edward L. Jones ◽  
Teresa S. Jones ◽  
...  
Keyword(s):  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Cutaneous Melanoma ◽  
Disease Specific Survival ◽  
Disease Specific

VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival

2018 ◽  
Vol 67 (7) ◽  
pp. 1113-1121 ◽  
Author(s):  
Lawrence F. Kuklinski ◽  
Shaofeng Yan ◽  
Zhongze Li ◽  
Jan L. Fisher ◽  
Chao Cheng ◽  
...  
Keyword(s):  
Cutaneous Melanoma ◽  
Inflammatory Cells ◽  
Disease Specific Survival ◽  
Primary Cutaneous Melanoma ◽  
Disease Specific

1140: Prognostic Nomogram for Disease-Specific Survival of Patients with Untreated Androgen Independent Prostate Cancer

2005 ◽  
Vol 173 (4S) ◽  
pp. 310-310
Author(s):  
Robert S. Svatek ◽  
Pierre I. Karakiewicz ◽  
Michael J. Shulman ◽  
Jose Karam ◽  
Paul Perrotte ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Disease Specific Survival ◽  
Disease Specific ◽  
Androgen Independent
Sign in / Sign up

Export Citation Format

Share Document